Exelixis Inc XNAS: EXEL

Strong Performer, Getting Expensive

43.53 -2.19 (-4.79%)

4.7M

XNAS Volume

XNAS 25 Jun, 2025 5:30 PM (EDT)

Postive Trial

Exelixis rises on Monday as its cancer drug combo shows positive results in phase-3 trial See details

Exelixis Inc quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents